TL;DR
Get everyday helpers delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA approved AbbVie’s once-daily pill Juvmo, also known as tavapadon during clinical trials, on Sept. 25, 2026, for treating Parkinson’s symptoms. Three 26-week trials found motor-symptom improvements when used alone and longer “on time” when added to existing medication; longer-term effects on impulse-control problems remain unclear.
The U.S. Food and Drug Administration approved Juvmo, AbbVie’s once-daily pill for Parkinson’s symptoms, on Sept. 25, 2026. The drug is approved as a standalone treatment for people with early Parkinson’s and as an add-on to existing medication in later stages, offering another option for managing motor symptoms.
Juvmo was called tavapadon during clinical trials. AbbVie tested it in three randomized, placebo-controlled Phase 3 trials, each lasting 26 weeks and enrolling more than 1,300 participants in total. Two trials studied the drug on its own, while a third assessed it as an addition to existing treatment.
According to the report, the standalone trials found improvements in motor symptoms, including issues such as tremor, rigidity and slowed movement. Reported side effects were generally mild to moderate and included nausea and headache. In the add-on trial, the drug helped extend “on time,” when medication is working, and reduce “off time,” when its effects wear away.
AbbVie expects Juvmo to be available in the United States in October 2026. The source report does not give a price, specific prescribing instructions or a detailed list of people who should not take it. Those practical details may become clearer as the drug reaches the market.
A Once-Daily Option for Symptom Control
Parkinson’s medicines can help control motor symptoms, but some existing treatments require doses multiple times a day. Managing a frequent schedule can add to the daily demands of living with the disease. Juvmo’s once-daily schedule may offer a different routine for eligible patients, though the report does not compare adherence or quality of life between Juvmo and other medicines.
The drug also has two approved roles: it can be used alone in early Parkinson’s or added to treatment in later stages. That range could give clinicians another option when tailoring symptom management. The trials’ reported motor improvements and changes in “on” and “off” time describe specific outcomes; they do not establish that Juvmo slows or stops the underlying progression of Parkinson’s.
How Juvmo Differs From Older Therapies
Parkinson’s disease involves the loss of neurons that produce dopamine, a chemical involved in movement. Many existing drugs called dopamine agonists mimic dopamine’s effects by activating D2 and D3 receptors. These treatments can help motor symptoms, but the source report notes that side effects may include dyskinesia, or uncontrolled movements, and impulse-control problems such as gambling.
Juvmo is described as targeting D1 and D5 receptors, activating different dopamine pathways. The report presents this mechanism as a distinction from older dopamine agonists; it does not establish that the new approach eliminates side effects. Cleveland Clinic neurologist Dr. Hubert Fernandez, a global investigator on two of the Phase 3 trials, said the approval gives health care providers “greater flexibility to tailor treatment to individual patient needs.”
““It’s not a huge game-changer, but definitely a nice additional tool to have.””
— Dr. Bryan Ho, Tufts Medical Center neurologist and director of its Movement Disorders Program, previously told Being Patient
Long-Term Effects Still Need Study
The trials lasted 26 weeks, so they do not settle whether Juvmo changes the longer-term risk of impulse-control problems. The source report specifically says the studies were not long enough to determine whether the treatment reduces that risk. It also does not provide long-term comparative results on side effects or symptom control.
The report describes nausea and headache as mild to moderate side effects in the standalone trials, but it does not provide detailed rates or a full safety profile. The FDA approval itself is confirmed; how the drug performs across broader and longer-term use remains to be seen.
U.S. Launch Expected in October
AbbVie expects U.S. availability in October 2026. As Juvmo reaches pharmacies and clinics, patients and clinicians will be able to assess its fit alongside existing Parkinson’s treatments. The source report does not specify an exact launch date, cost or additional studies planned after approval.
Key Questions
What did the FDA approve?
The FDA approved Juvmo, AbbVie’s once-daily pill for Parkinson’s symptoms, on Sept. 25, 2026. It was called tavapadon during clinical trials.
Who is Juvmo approved for?
It is approved as a standalone treatment in early Parkinson’s and as an add-on to existing medication in later stages, according to the source report.
How does Juvmo work?
The report says Juvmo activates D1 and D5 dopamine receptors. Many existing dopamine agonists instead activate D2 and D3 receptors.
What did the trials find?
Three 26-week Phase 3 trials found motor-symptom improvements when Juvmo was used alone. In the add-on trial, it helped extend “on time” and reduce “off time.”
When is Juvmo expected to be available?
AbbVie expects the drug to be available in the United States in October 2026; the report does not give a specific date.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
